Genmab A/S presented new data at the ASH Annual Meeting showing the potential of epcoritamab in treating DLBCL and FL. In the EPCORE DLBCL-3 trial, epcoritamab monotherapy showed an overall response rate of 73% in elderly patients with DLBCL. Arm 8 of the EPCORE NHL-2 trial demonstrated an overall response rate of 93% and a complete response rate of 86% in elderly patients with newly diagnosed DLBCL. Arm 1 of the same trial showed durable remissions lasting over three years in most patients with DLBCL. Arm 3 of the EPCORE NHL-2 trial revealed deep and durable responses in FL patients treated with epcoritamab plus BR. A study found a decrease in peripheral CD4+ T cells and an increase in CD8+ T cells after the first full dose of epcoritamab, leading to a reduced CD4:CD8 ratio. Results from the Phase 2 EPCORE DLBCL-3 trial showed a 73% overall response rate, with 62% of patients achieving a complete response. Safety data revealed common adverse events like CRS, diarrhea, and fatigue. Epcoritamab demonstrated promising results as a chemotherapy-free option for elderly patients with comorbidities in diffuse large B-cell lymphoma. Epcoritamab is currently being studied in Phase 1b/2 and Phase 2 trials for B-cell non-Hodgkin lymphoma, offering potential hope for patients in need of new treatment options. Genmab’s Epcoritamab, developed with DuoBody-CD3 technology, has been approved in certain lymphoma indications and is easily accessible. Co-developed with AbbVie, the therapy is undergoing evaluation in various hematologic malignancies, including in combination therapies. Four Phase 3 trials are ongoing to assess its safety and efficacy. Genmab aims to transform cancer treatment by 2030 through innovative antibody therapeutics. The company’s international presence and focus on next-generation technologies position it as a key player in the biotechnology sector. For more information on Genmab’s initiatives and trials, visit their website. 1. The stock market experienced a significant drop today, with the Dow Jones Industrial Average falling by over 500 points due to concerns about rising inflation and interest rates.

2. A new study released by the CDC shows that the number of measles cases in the US has reached a 25-year high, with over 700 reported cases this year alone.

3. The Trump administration announced plans to impose tariffs on $11 billion worth of EU goods in retaliation for subsidies given to Airbus, escalating trade tensions between the US and Europe.

4. The latest jobs report revealed that the US economy added 196,000 jobs in March, exceeding expectations and pointing to continued strength in the labor market.

5. Researchers have discovered a new species of dinosaur in Tanzania, named Mnyamawamtuka moyowamkia, which lived over 100 million years ago and belonged to the long-necked, plant-eating sauropods.

Read more at 1. Coca-Cola reports a 13% increase in revenue for the second quarter of 2021, reaching $10.1 billion. – CNBC

2. Amazon announces plans to hire 55,000 corporate and technology employees globally, with average compensation exceeding $150,000. – Wall Street Journal

3. Pfizer and BioNTech agree to supply the U.S. government with 200 million additional doses of their COVID-19 vaccine, boosting total deliveries to 500 million. – Reuters

4. Tesla’s revenue for the second quarter reaches $11.96 billion, beating analysts’ expectations and marking a 98% year-over-year increase. – CBS MarketWatch: Genmab Announces Data From Multiple Clinical Trials Showing